RxDoctor Payments Data

Herbert Aronow, MD

Interventional Cardiology · Ypsilanti, MINPI 1235106766

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.1%. 2025 is the largest year on record at $10,863, 3.3 times the $3,315 reported in 2019.

$24,973in general payments, 2019–2025

Across 74 payments — averaging $337.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$6K
  • Recor Medical Inc$5K
  • Medtronic$5K
  • Silk Road Medical, Inc.$3K
  • GE HealthCare$2K
  • Philips North America LLC$2K
  • plus $2K from 9 others
$436,011in research payments, 2019–2025

Across 38 payments — averaging $11,474 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$394K
  • Philips North America LLC$30K
  • Cardiovascular Systems Inc.$12K

What the payments were for

  • Consulting fees$14,88960%
  • Speaking & faculty fees$2,67511%
  • Travel & lodging$3,68715%
  • Food & beverage$3,72315%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,973 in reported general payments places this provider in the 80th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$41,955
Medicare patients
101
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium48$547
ClopidogrelClopidogrel Bisulfate18$345
Ezetimibe18$248
Rosuvastatin Calcium11$235
Metoprolol Succinate12$130

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Ypsilanti

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →